Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol

Kai He(Shanghai Jiao Tong University), Hui Li(Los Alamos National Laboratory), Wanjun Jiang(Tsinghua University), Yuexiang Bian(Shanghai Jiao Tong University), You Wang(Renji Hospital), B Zhang(Renji Hospital), ADila ABuduaini(Shanghai Jiao Tong University), Hong Wu(Ministry of Education of the People's Republic of China), Zeyu Huang(Renji Hospital), Fengyuan Chen(Renji Hospital), Rong Shao(Renji Hospital), Peixuan Ji(Shanghai Jiao Tong University), Yawen Lu(Shanghai Jiao Tong University), Chaoyun Shen(Shenzhen Metro (China)), Wenyi Gu(Shanghai Jiao Tong University), Yunxin Zhao(Renji Hospital), Xiaoyan Yan(Peking University), Lingling Gao(Peking University), Yunxia Gan(Renji Hospital), Lianyong Liu(Punan Hospital), Chen Yao(Peking University), Jianyi Wei(Shanghai Jiao Tong University)
BMJ Open
May 1, 2026
Cited by 0


Related Papers